Publications

Publications

Scientific Manuscripts

ACCELERATE scientific manuscripts

2024

2023

2022

2021

6th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

2020

PSF for medicinal product development of epigenetic modifiers for children

5th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Medicinal product development of epigenetic modifiers for children

Paerson et al., European Journal of Cancer November 2020; 139:135-148

read more
PSF for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents

4th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Medicinal product development for acute myeloid leukaemia in children and adolescents

Pearson et al., European Journal of Cancer, European Journal of Cancer September  2020; 136:116-129

read more
The RACE to accelerate drug development for children with cancer

The RACE to accelerate drug development for children with cancer

The Lancet Child & Adolescent Health

Pearson, A. et al.

August 2020

read more
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for Medicinal Product Development for Mature B-cell Malignancies in Children
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for Medicinal Product Development of Checkpoint Inhibitors for Use in Combination Therapy in Paediatric Patients

2015-2019

Implementation of mechanism of action biology-driven early drug development for children with cancer
Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer
View more

Other relevant manuscripts

Other relevant publications section contain articles from the childhood cancer community which concern ACCELERATE. Various publications can be found here which are relevant to ACCELERATEs mission and/or childhood cancer patient drug development, etc.

Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE)

Ferrari, A. et al., 2021. ESMO OPEN

read more
Inclusion of Adolescents in Adult Clinical Trials: Report of the Institute for Advanced Clinical Trials for Children’s Pediatric Innovation Research Forum. Therapeutic innovation & regulatory science
Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to EMA and US FDA

Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to EMA and US FDA

Reaman, G., Karres D. et al., JCO, September 2020

read more
Pediatric cancer research: Surviving COVID‐19
Can a multi‐stakeholder prioritisation structure support regulatory decision making? A review of paediatric oncology strategy forums reflecting on challenges and opportunities of this concept
Will the revised class waiver list make it?
New drugs for children and adolescents with cancer: the need for novel development pathways
Is the European pediatric medicine regulation working for children and adolescents with cancer?
View more

ACCELERATE Platform

Annual Work Plan

6th ACCELERATE Paediatric Strategy Forum in collaboration with the European Medicines Agency and with the participation of the Food and Drug Administration: Anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
PSF for medicinal product development of epigenetic modifiers for children

ACCELERATE Work Plan 2018

read more
PSF for Medicinal Product Development for Acute Myeloid Leukaemia in Children and Adolescents

ACCELERATE Work Plan 2017

read more
The RACE to accelerate drug development for children with cancer

ACCELERATE Work Plan 2016

read more
View more

Executive Summaries

Annual Conference 2022

Paediatric Strategy Forums

View more

Abbreviations

ALK: anaplastic lymphoma kinase

BPCA: Biologics Price Competition & Innovation

CDDF: Cancer Drug Development Forum

EMA: European Medicines Agency

ENCCA: European Network for Cancer Research in Children and Adolescents

FDA: Food and Drug Agency

IMI: Innovative Medicine Initiative

ITCC: Innovative Therapies for Children with Cancer

LTFU: long-term follow-up

MA: marketing authorisation

MoA: Mechanism of Action

PDCO: Paediatric Committee [of the EMA]

PIP: Paediatric Investigation Plan

PK: pharmacokinetic

PPoC: paediatric proof of concept

PREA: Pediatric Research Equity Act

PRINTO: Paediatric Rheumatology International Trials Organisation

SIOPE: European Society for Paediatric Oncology

US[A]: United States [of America]

TYA: teenagers and young adults

WG: Working Group

WR: written requests

Share by: